The research aimed to outline the characteristics of four subtypes of breast cancers with the aid of analysing awesome protein expression signatures in Luminal A, Luminal B, HER2-wonderful, and triple-poor breast cancer. Utilising superior proteomic technology together with mass spectrometry and antibody- primarily based assays, the research needs to enhance the class of breast cancer subtypes and discover potential bio-markers for personalised treatment. The analysis showed the heterogeneity of breast cancers on the molecular stage, validating the importance of installed markers like estrogen and progesterone receptors in Luminal subtypes and HER2 in HER2-fine cancers. Novel protein signatures had been recognised in triple-negative breast cancer, high lighting the role of proteins worried in DNA restore and epithelial-to-mesenchymal transition, which contributes to the aggressive nature of this subtype. The study also validated the capacity of proteomic facts to refine the PAM50 category device, presenting a more nuanced information of breast cancer subtypes. The findings endorse that integrating proteomics with other omics facts should enhance personalised treatment approaches, in the long run improving affected person results. Despite the treasured insights received, the study mentioned the need for further studies, mainly longitudinal research to set up causal relationships among protein expression signatures and medical consequences.
PLEASE NOTE: You must be a member of the University of Lincoln to be able to view this dissertation. Please log in here.